teamwork

Houston incubator announces merger with local nonprofit

Grace Rodriguez, CEO and executive director of Impact Hub Houston, and Jeff Reichman, founder of Sketch City, have announced a partnership between their organizations. Photos courtesy

Two Houston organizations that have partnered for three years to provide a platform for innovation and ideation have announced a more formalized partnership.

Impact Hub Houston, a global impact innovation incubator, and Sketch City, a nonprofit focused on advancing technology and data in public decision making and social good, have announced the merger of Sketch City into a new initiative under Impact Hub Houston: Code for Houston.

"We're honored to continue Sketch City's work of connecting Houston's tech talent with civic innovation opportunities through Code for Houston," says Grace Rodriguez, CEO and executive director of Impact Hub Houston, in a news release. "From our response and recovery collaboration after Hurricane Harvey to our ongoing events that help diverse do-gooders and developers collaborate on and create impactful solutions for Houston, we have established a strong track record of effective #Tech4Good initiatives."

The two organizations have worked together to host Open Project Night and the Houston Hackathon over the past few years. Jeff Reichman, principal at Houston-based data science consulting firm January Advisors, founded Sketch City in 2016.

"We are so excited to join forces with Impact Hub Houston," Reichman says in the release. "Their mission is directly aligned with ours. Sketch City began as a way to connect people with shared interests in technology, data, and civic improvement. Within a few years, it has grown into a community of thousands of people who live all over the world."

The merger comes following the impact of the COVID-19 pandemic — something Reichman says has led him to rethink how Sketch City operates.

"Merging Sketch City with Impact Hub Houston feels like a natural extension of the work we've done together; and it creates additional administrative capacity for programming and community growth," Reichman continues in the release. "Sketch City's efforts will continue under Impact Hub Houston's 'Code for Houston' initiative. I'm thrilled to be a part of that new chapter."

Sketch City and its initiatives will roll into Code for Houston, a new initiative under Impact Hub Houston that aligns with Code for America — a national organization that works with community organizations and governments to build digital tools, change policies, and improve public programs.

Code for Houston will streamline operations for Impact Hub Houston's annual hackathons, which includes the Houston Hackathon and Climathon Houston, as well as expand resources and support for Houston's changemakers and civic technologists who want to transform their ideas into viable triple-bottom-line businesses and impact ventures, per the release.

"We look forward to continuing Sketch City's legacy of strengthening and activating relationships between Houston's tech talent and diverse communities," Rodriguez continues.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted